East Tennessee State University
Chronic Olanzapine Treatment Eliminates Cognitive Deficits Produced by Neonatal Quinpirole Treatment.
Abstract
dc:description.abstract<p>This study evaluated the effects of chronic olanzapine treatment on cognitive performance and neurochemical function in a rodent model of schizophrenia. Animals were neonatally treated with quinpirole, a dopamine D<sub>2</sub> receptor agonist, or saline. Quinpirole treatment produces an increase of dopamine D<sub>2</sub> receptor sensitivity that extends into adulthood, known as D<sub>2</sub> receptor priming, similar to a phenomenon that occurs in schizophrenia. These same rats were treated in adulthood for 28 days with olanzapine, an atypical antipsychotic, or saline. Dopamine D<sub>2</sub>- primed rats demonstrated significant deficits on a cognitive task that were alleviated by olanzapine treatment. Brain tissue analysis revealed that D<sub>2</sub>-primed animals demonstrated a significant decrease in the neurotrophins nerve growth factor (NGF) in the hippocampus and brain-derived neurotrophic factor (BDNF) in the frontal cortex. Olanzapine treatment alleviated the decrease in NGF. The results suggest that olanzapine eliminates cognitive impairment and may have neuroprotective properties in the hippocampus of D<sub>2</sub>-primed rats.</p>
Degree
thesis:*- Name thesis:degree_name
- MA (Master of Arts)
- Level thesis:degree_level
- Thesis - unrestricted
- Discipline thesis:degree_discipline
- Psychology
- Year dc:date.issued
- 2005
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Thacker, Stephanie K
Subjects
dc:subject × 8Rights
dc:rights- Statement dc:rights
-
- Copyright by the authors.
Identifiers
dc:identifier.*- Repository record dc:identifier
- https://dc.etsu.edu/etd/1011
- OAI identifier oai:identifier
- oai:dc.etsu.edu:etd-2168